Bank CEOs meet with Trump to discuss Fannie Mae and Freddie Mac - Bloomberg
PITTSBURGH - Viatris Inc. (NASDAQ:VTRS), a global healthcare company with a market capitalization of $10.27 billion and a significant 5.58% dividend yield, has announced successful completion of two Phase 3 studies for its novel pain medication MR-107A-02, showing significant pain improvement and reduced opioid use. According to InvestingPro analysis, Viatris stands as a prominent player in the pharmaceuticals industry, with analysts expecting profitability this year despite recent challenges. The trials, involving patients post-herniorrhaphy and bunionectomy surgeries, demonstrated the drug’s efficacy in managing moderate-to-severe acute pain.
The primary measure, the Sum of Pain Intensity Difference over 48 hours, indicated that MR-107A-02 was substantially better than placebo. In the herniorrhaphy study, 72.6% of patients treated with MR-107A-02 were opioid-free compared to 58.6% with placebo. In the bunionectomy study, these figures were 56.9% and 33.1%, respectively. Moreover, the drug provided faster pain relief when compared to both placebo and the opioid comparator, tramadol. For investors tracking healthcare innovations, InvestingPro research reports offer comprehensive analysis of 1,400+ stocks, including detailed insights into pharmaceutical companies’ R&D pipelines and market potential.
Safety profiles were favorable, with the incidence of treatment-emergent adverse events similar to placebo. No severe adverse events leading to death were reported.
Philippe Martin, Viatris’s Chief R&D Officer, highlighted the potential for MR-107A-02 to become a first-line treatment for acute pain without the risks associated with opioids. Anesthesiologist Dr. Todd Bertoch also praised the consistency of positive data across different pain models.
Viatris plans to submit a New Drug Application to the FDA by the end of 2025, aiming to offer a non-opioid alternative for pain management. The full results of the studies will be presented at future medical conferences, including PAINWeek 2025. With a strong free cash flow yield and current undervaluation according to InvestingPro Fair Value metrics, the company appears well-positioned to support its R&D initiatives while maintaining its attractive dividend payments to shareholders.
This announcement is based on a press release statement from Viatris Inc.
In other recent news, Viatris Inc. has been active with several significant developments. The company announced a settlement framework to resolve opioid-related claims in the United States, agreeing to pay up to $335 million over nine years. This settlement aims to support state and local efforts against opioid issues and has been accounted for in Viatris’ financial planning. Additionally, Viatris has submitted applications for the approval of Effexor SR Capsules to treat generalized anxiety disorder (GAD) in Japan, marking a potential first in the country where no treatments are currently approved for GAD.
In corporate developments, Viatris appointed Frank D’Amelio and Michael Severino to its Board of Directors, while Rajiv Malik and Harry Korman will retire at the end of their terms. The company also named Hemanth J. Varghese as the new Chief Strategy Officer, bringing his extensive experience to the executive leadership team. On the financial front, Jefferies analyst Glen Santangelo adjusted the price target for Viatris stock to $13.00, down from $15.00, while maintaining a Buy rating. This revision follows the company’s fourth-quarter earnings and 2025 financial guidance, with expectations of 3% organic growth by fiscal year 2025. Despite challenges, the analyst remains optimistic about Viatris’ performance and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.